LEA29Y (Belatacept) Emory Edmonton Protocol (LEEP) (CIT-04) and Extended Follow Up after Islet Transplantation in Type 1 Diabetes (CIT-08)

CIT-04: This trial is a prospective, two-center, open-label, pilot study of islet transplantation assessing the safety and efficacy of a steroid-free, calcineurin inhibitor-free based immunosuppressive regimen with belatacept in subjects with long-standing type 1 diabetes (T1D) that is refractory to intensive insulin therapy. CIT-08: The purpose of this protocol is to collect long-term follow-up information on the safety and efficacy of islet transplantation in CIT subjects after their completion in their CIT parent study.